

Table SI. Target information of shRNA LGALS3.

ID	Target sequence	Start location (bp)	GC (%)
LGALS3-shRNA	TGCCTCGCATGCTGATAACAA	468	47.62
shRNA, short hairpin RNA.			

Table SII. Sequence of LGALS3 shRNA.

ID	5'	Stem	Loop	Stem	3'
LGALS3-shRNA-a	Ccgg	TGCCTCGCATGCTGATAACAA	CTCGAG	TTGTTATCAGCATGCGAGGCA	TTTTTg
LGALS3-shRNA-b	aattcaaaaa	TGCCTCGCATGCTGATAACAA	CTCGAG	TTGTTATCAGCATGCGAGGCA	/

shRNA, short hairpin RNA.

Table SIII. Sequences of primers used in the present study.

Method	Name of primer	Sequence	Length of products, bp
Reverse transcription-quantitative PCR	Galectin-3	5'-ACAATTCTGGGCACGGTGAA-3'	227
		5'-ATAAGCTCCAGGTGCTCCAGG-3'	
	GAPDH	5'-GTCAGTGGTGGACCTGACCT-3'	380
		5'-TGAGGAGGGGAGATTCAGTG-3'	
	IL-8	5'-ATGACTTCCAAGCTGGCCGTGGCT-3'	268
		5'-TCTCAGCCCTCTTCAAAAACCTTCTC-3'	
	MMP-9	5'-TGCGCTACCACCTCGAACTT-3'	181
		5'-GATGCCATTGACGTCGTCCT-3'	

Table SIV. Association between the expression level of gal-3 and TNM stage of patients with nasopharyngeal carcinoma.

TNM stage	Cases, n	Expression level of gal-3		P-value
		Low expression, n (%)	High expression, n (%)	
T classification				
T1-2	16	3 (18.7)	13 (81.3)	0.28
T3-4	24	1 (4.2)	23 (95.8)	
N classification				
N0	5	0 (0)	5 (100)	1
N1-3	35	4 (11.4)	31 (88.6)	
TNM clinical stage				
I-II	5	1 (20)	4 (80)	0.43
III-IV	35	3 (8.6)	32 (91.4)	

The Fisher's exact test was used to analyze the expression levels of gal-3 in patients with nasopharyngeal carcinoma at different TNM stages. Gal-3, Galectin-3.